A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam

Inclusion Criteria: * Ages 18-40. * Male. * Subjects have standard weight( generally not less than 50 kg), and body mass index (BMI) within 19-25. * All physical examinations( including ECG, kidney function, liver function, blood routine, urine routines, etc) are normal. * Subjects have no history of significant diseases, allergy or orthostatic hypotension. * All subjects sign the informed consent after being informed all possible adverse drug reaction and .are able to complete all examination defined. Exclusion Criteria: * Subjects who cannot communicate with medical staff, and subjects with cerebral insufficiency or psychological problem. * Partner of subjects have plan to pregnant. * Subject have primary disease in vital organ. * Subjects have a history of drug dependence or psychosis in last 2 years. * Subjects with severe blood loss or blood donation more than 200 mL in the prior 3 months. * Subjects who have participated in another clinical trial within the prior 3 months. * Known or suspected to have a history of alcohol or drug abuse. * Subjects who have abnormal clinical significance after checking preclinical laboratory data and physical examinations. * Known allergy to pharmaceutical ingredient of Ginkgolides Meglumine Injection or allergy sufferers who are allergic to more than two kinds of food or drugs in the past. * Subjects who have used any drugs in the prior 2 weeks. * Subjects have unexplained infections. * The subjects could not complete the study in the opinion of the Principal Investigator due to any reason. * Subjects who test positive at screening for human immunodeficiency virus (HIV), hepatitis C virus (HCV) , hepatitis B surface antigen (HbsAg), etc.